Stockscreener 앱 받기
23.58
3.72%
-0.91
시간 외 거래:
23.94
0.36
+1.53%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Where are the Opportunities in (BEAM) - Stock Traders Daily
Quest Partners LLC Grows Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Prime Editing and CRISPR Market Trends and Growth Opportunities - openPR
Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat
Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat
FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com
Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan
Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat
Beam Therapeutics president sells $1.35 million in stock - Investing.com India
Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com
Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK
ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey
Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat
William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance
Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN
Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN
Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com
Beam points to positive data with key base editing asset - pharmaphorum
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance
Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks
Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL
Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights
SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online
Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News
Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada
JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Beam’s early base editing clinical data overshadowed by patient death - The Business Journals
Beam Therapeutics to Present Data Across Hematology - GlobeNewswire
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Posts Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data By Investing.com - Investing.com UK
Beam stock falls after fatality in gene editing trial - Seeking Alpha
Sickle cell patient dies in Beam study of base editing therapy - BioPharma Dive
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics' Sickle Cell Treatment Shows Promising Results in First Clinical Trial | BEAM Stock News - StockTitan
Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - STAT
0.93%
3.55%
자본화:
|
볼륨(24시간):